Patent Invalidation in Brussels.

A patent invalidation Brussels litigation team can rely on has to match where the disputes are fought — and Brussels is unusual. Belgium concentrates every patent case in one place: since 1 January 2015 the Brussels Enterprise Court (tribunal de l’entreprise / ondernemingsrechtbank) has held exclusive national first-instance jurisdiction over patent infringement and invalidity, with appeals to the Brussels Court of Appeal. Brussels is also the seat of a Unified Patent Court local division and of the EU regulatory apparatus that shapes pharma exclusivity. PerspireIP builds invalidity-grade prior-art searches for the accused parties, generics entrants and counsel fighting weak or overbroad patents across Belgium, the EPO and the UPC.

Where a patent invalidation Brussels case is actually heard

Belgium has centralised all patent litigation in a single forum. Since 1 January 2015 the Brussels Enterprise Court (tribunal de l’entreprise / ondernemingsrechtbank) has held exclusive national jurisdiction in first instance over patent infringement and over invalidity (nullity) actions, wherever in Belgium the dispute arises. Appeals go to the Brussels Court of Appeal, and a further appeal on points of law lies to the Court of Cassation.

The legislator built this single-court design to raise the quality and consistency of patent judgments. It also means the prior art is decisive: in a Belgian nullity action the accused party asks the Brussels court to revoke the patent for lack of novelty or inventive step, and the outcome turns on what was publicly available before the priority date. Where a patent is revoked in whole or in part, an appeal or a Cassation appeal has suspensive effect — so the record built at first instance matters enormously.

• Brussels Enterprise Court — exclusive first-instance court for Belgian infringement and nullity
• Brussels Court of Appeal — hears all Belgian patent appeals
• EPO Opposition Division — central attack on a European patent within nine months of grant
• Unified Patent Court — revocation of unitary and non-opted-out European patents

Two forums for one European patent: the Brussels court or the UPC

Belgium is a full Unified Patent Court member, and Brussels hosts its own local division — sitting at the City Atrium on Rue du Progrès 50, alongside the federal economy administration. That gives an accused party a genuine choice. If a European patent has not been opted out of the UPC, its Belgian designation can be invalidated either before the Brussels Enterprise Court or before the Unified Patent Court, and the two systems carry very different reach and cost.

The Brussels local division is also linguistically flexible: it accepts French, Dutch, German or English as the language of proceedings, which suits Belgium’s bilingual capital and cross-border filers. A national nullity action revokes only the Belgian part of the patent; a UPC revocation can strike the patent across every participating state in one judgment. Choosing between them is a strategic call — but both stand or fall on the strength of the prior art, so a patent invalidation Brussels defendant needs an invalidity search that works in either forum.

Pharma, biologics and SPCs: where Brussels patent fights come from

Belgium hosts one of Europe’s densest concentrations of biopharmaceutical capacity, and that shapes what gets litigated. Homegrown UCB — which alone absorbs a large share of national pharma R&D — sits alongside major sites for GSK (its vaccine hubs at Wavre, Rixensart and Gembloux), Janssen and Takeda. Around the capital, chemicals, biologics manufacturing and one of Europe’s busiest logistics corridors add further patent-heavy industry.

Pharma is where invalidity work concentrates. When a blockbuster nears loss of exclusivity, generic and biosimilar entrants clear the path by attacking the patents and supplementary protection certificates that guard it. Belgian SPCs for medicines and plant-protection products are granted by the OPRI/DIE in Brussels, and an SPC is only as strong as the basic patent behind it. Local disputes therefore cluster around formulations, dosage regimens, biologics, second-medical-use claims and process patents — not consumer electronics.

Belgian nullity, EPO opposition or UPC revocation: three routes

An accused party in Brussels usually has more than one way to attack a patent, and the routes are not interchangeable. A Belgian nullity action runs before the Brussels Enterprise Court and revokes the Belgian designation, whether brought as a standalone claim or as a counterclaim to an infringement suit. EPO opposition is a central attack: filed within nine months of grant, it can knock out the European patent in every designated state at once, decided on novelty and inventive step.

The Unified Patent Court adds a third route. A UPC revocation action can kill a unitary patent, or a European patent that has not been opted out, across all participating states in a single judgment — and it can be run before the Brussels local division or a central division seat. For pharma, supplementary protection certificate validity is closely tied to the underlying patent, so the same attack often reaches both.

The routes share one dependency: prior art. One rigorous invalidity search, charted claim by claim, can feed a Brussels nullity counterclaim, a nine-month EPO opposition and a UPC revocation at the same time, so the same evidence set works across every forum an accused party might choose.

Where pharma and chemistry prior art actually lives

Chemistry and life-science patents are anticipated in a different literature than electronics or software. Much of the decisive art never appears in a patent database at all — it lives in the peer-reviewed journal record and in specialist compound and sequence collections. A credible invalidity search in this field has to reach those sources and prove the public-availability date of each one against the claim’s true priority date.

• Chemical Abstracts (CAS) and the peer-reviewed journal literature, where a synthesis, formulation or compound may first be disclosed
• Sequence and structure databases for biologics, antibodies and nucleic-acid claims
• Older and abandoned patent families, often argued as inventive-step combinations under EPO problem-and-solution
• Regulatory dossiers, conference abstracts, theses and dated technical disclosures that predate the priority date

For a second-medical-use or dosage-regimen claim — common in the SPC fights around Brussels pharma — the anticipating reference is frequently an older clinical paper or an abandoned family, not the headline blockbuster. We treat dating as evidence to be proved, establishing that each reference was genuinely public before the priority date the claim actually relies on.

The EU capital, logistics and cross-border enforcement

Brussels is the seat of the European Commission, the Council and the European Parliament, and the EU’s regulatory choices — on marketing authorisations, SPC policy and unitary patents — are made here. None of those institutions hears a patent case. Patent venue in Belgium is a separate, specialised system: infringement and validity go to the Brussels Enterprise Court, European patents are opposed at the EPO in Munich, and unitary patents are revoked at the UPC. Proximity to the EU institutions confers no patent forum.

Belgium’s position as a logistics and chemicals hub at the heart of the Benelux also means patents rarely stop at the border. A family asserted in Belgium often has Dutch, German and French siblings enforced before those national courts or the UPC’s local divisions. That is why the invalidity evidence has to travel across jurisdictions and languages — French, Dutch, German and English — so a reference that anticipates a claim in Brussels also carries weight in an EPO opposition or a parallel proceeding elsewhere.

How PerspireIP builds a patent invalidation Brussels case can rely on

Every engagement follows the same disciplined path. We map the asserted claims element by element, fix the priority date that actually governs each one, and search against that date rather than the filing date on the cover. For pharma, biologics and chemistry subject-matter we run patent and deep non-patent-literature searching in parallel — CAS, journals, sequence and structure databases — then build claim charts a Brussels judge, an EPO Opposition Division or a UPC panel can follow.

• Claim charting mapped to novelty and inventive step under the EPC and Belgian law
• Deep retrieval across CAS, peer-reviewed journals, sequence databases and older patent families
• Public-availability dating for every reference, evidenced in French, Dutch, German and English
• Prior art sized to your forum — a Brussels Enterprise Court nullity action, the nine-month EPO opposition window, or UPC revocation
• A written invalidity analysis and reference packages ready for the court, the EPO or the UPC

We work alongside your Belgian and European counsel as a specialist search partner, deliver to Brussels, EPO and UPC deadlines, and keep every engagement confidential. Whether you are a manufacturer facing an assertion, a generics or biosimilar entrant clearing a path around an SPC, or litigation counsel preparing a cross-border defence, we scale to fit — a single search, a multi-patent campaign or ongoing support. Send us the patent number and your key dates, and we will scope a patent invalidation Brussels project within one business day.

IP Landscape & Resources in Brussels

Key intellectual-property authorities and venues relevant to Brussels:

• Belgian Office for Intellectual Property (OPRI/DIE) — the Belgian patent office, part of the FPS Economy in Brussels; grants Belgian patents and supplementary protection certificates for medicines
• Belgian Federal Justice (courts) — the Belgian judiciary; the Brussels Enterprise Court holds exclusive national jurisdiction over patent infringement and nullity, with appeals to the Brussels Court of Appeal
• European Patent Office (EPO) — grants European patents and runs post-grant opposition, a central attack filed within nine months of grant
• Unified Patent Court (UPC) — hears revocation of unitary and non-opted-out European patents; Belgium hosts a UPC local division in Brussels

Request a Patent Invalidation Search in Brussels

Explore related PerspireIP services: Patent Invalidation · Prior Art Litigation Search · Patent Infringement Analysis.

Frequently Asked Questions